Loop diuretics

1. Introduction

Loop diuretics are a potent class of diuretics used in the treatment of conditions characterized by fluid overload, such as congestive heart failure (CHF), chronic kidney disease (CKD), acute pulmonary edema, and cirrhosis. They act primarily on the thick ascending limb of the loop of Henle in the nephron, where they inhibit sodium, potassium, and chloride reabsorption, leading to profound diuresis. Their pharmacodynamic efficacy surpasses that of thiazide diuretics and potassium-sparing diuretics, making them the first-line agents for rapid fluid removal, especially in emergency settings.

Loop diuretics are also used in electrolyte management, particularly hypercalcemia and hyperkalemia, and play a critical role in managing hypertension in patients with coexisting renal impairment or volume overload.

---

2. Mechanism of Action

Loop diuretics inhibit the Na⁺-K⁺-2Cl⁻ symporter (NKCC2) located in the luminal membrane of epithelial cells in the thick ascending limb of the loop of Henle.

This blockade leads to:

• Increased excretion of Na⁺, Cl⁻, K⁺, Ca²⁺, and Mg²⁺

• Reduced medullary hypertonicity, impairing the kidney's ability to concentrate urine

• Enhanced water excretion due to natriuresis

• Secondary volume depletion, leading to activation of the renin-angiotensin-aldosterone system (RAAS)

• Venodilation (with intravenous administration), reducing preload in heart failure

These mechanisms result in powerful and rapid diuretic effects, particularly useful in conditions requiring immediate fluid removal.

---

3. Pharmacokinetics and Pharmacodynamics

Property	Details
Bioavailability	Varies by agent (Furosemide ~50%, Torsemide ~80%)
Onset of Action	Oral: 30–60 min; IV: 5 min
Duration	6–8 hours (shorter for furosemide)
Protein Binding	High (~95% for furosemide and torsemide)
Metabolism	Torsemide: hepatic; Furosemide: minimal
Elimination	Renal (mostly unchanged)

Loop diuretics exhibit a ceiling effect, meaning doses above a certain threshold do not increase diuresis but heighten toxicity risk.

---

4. Generic and Brand Names

Common Generic Agents:

1. Furosemide

2. Bumetanide

3. Torsemide

4. Ethacrynic acid (used when sulfa allergy is present)

Brand Names:

• Furosemide: Lasix

• Bumetanide: Bumex

• Torsemide: Demadex

• Ethacrynic acid: Edecrin

---

5. Indications

1. Congestive Heart Failure – acute and chronic volume overload

2. Edema due to renal, hepatic, or cardiac causes

3. Pulmonary edema – acute decompensated heart failure

4. Hypertension – particularly with CKD or volume overload

5. Hypercalcemia – alongside hydration

6. Hyperkalemia – adjunct to potassium-lowering therapies

7. Nephrotic syndrome – to manage fluid retention

8. Acute kidney injury (AKI) – limited role in fluid management

9. Cirrhosis with ascites – in combination with aldosterone antagonists

---

6. Dosage and Administration

Drug	Oral Dose Range	IV Dose Range	Notes
Furosemide	20–80 mg once/twice daily	20–40 mg IV	Short half-life, erratic PO absorption
Bumetanide	0.5–2 mg once/twice daily	0.5–1 mg IV	Potent, predictable PK
Torsemide	10–20 mg daily	10–20 mg IV	Longer half-life, hepatic metabolism
Ethacrynic acid	25–50 mg oral	50 mg IV	No sulfa group; ototoxic risk

Equivalence:

• Furosemide 40 mg ≈ Bumetanide 1 mg ≈ Torsemide 20 mg ≈ Ethacrynic acid 50 mg

Titration:

• Dosing should be titrated to clinical response (e.g., weight loss, urine output, edema resolution)

• Monitor renal function and electrolytes during therapy

---

7. Side Effects

System/Organ	Adverse Effects
Renal	Prerenal azotemia, AKI, volume depletion
Electrolytes	Hypokalemia, hypomagnesemia, hyponatremia, hypocalcemia
Metabolic	Hyperuricemia (gout), hyperglycemia, dyslipidemia
Ototoxicity	Especially with high-dose IV furosemide or ethacrynic acid
Cardiovascular	Orthostatic hypotension, arrhythmias from electrolyte imbalances
Allergic Rxns	Sulfa allergy cross-reactivity (except ethacrynic acid)

8. Contraindications

• Anuria

• Severe hypovolemia or electrolyte depletion

• Hypersensitivity to sulfonamide-derived drugs (except ethacrynic acid)

• Hepatic coma (cautious use to prevent encephalopathy)

• Allergy to loop diuretics

---

9. Precautions

1. Electrolyte Monitoring: Especially K⁺, Mg²⁺, and Na⁺

2. Volume Status: Avoid excessive diuresis leading to hypovolemia

3. Kidney Function: Monitor BUN, creatinine; watch for prerenal AKI

4. Hearing Assessment: Avoid ototoxic doses and combinations with aminoglycosides

5. Diabetes Mellitus: May worsen glycemic control

6. Gout: Loop diuretics can precipitate attacks due to uric acid retention

7. Pregnancy: Use only if benefits outweigh risks (category C)

---

10. Drug Interactions

Interacting Agent	Interaction Outcome
Aminoglycosides	Enhanced ototoxicity
NSAIDs	Attenuated diuretic effect (↓ renal prostaglandins)
ACE inhibitors/ARBs	Risk of hypotension and AKI when combined
Lithium	Reduced lithium clearance → lithium toxicity
Digoxin	Hypokalemia potentiates digoxin toxicity
Thiazide diuretics	Synergistic diuresis but ↑ electrolyte disturbances
Corticosteroids	↑ Hypokalemia risk
SGLT2 inhibitors	↑ Hypotension and dehydration risk

11. Use in Special Populations

A. Elderly

• Increased sensitivity to hypotension and electrolyte shifts

• Lower initial doses recommended

B. Pediatrics

• Used for heart failure, edema; weight-based dosing is essential

C. Pregnancy and Lactation

• Furosemide is used when benefits outweigh risks

• Not first-line unless clinically justified

D. Renal Impairment

• Diuretic resistance common

• High-dose loop diuretics or continuous infusion may be necessary

• Monitor for nephrotoxicity and AKI

---

12. Diuretic Resistance

Patients may develop diuretic resistance, especially in advanced HF or CKD.

Mechanisms:

• Neurohormonal activation (RAAS, ADH)

• Distal tubular hypertrophy

• Hypoalbuminemia reducing delivery to site of action

• GI edema impairs absorption (oral agents)

Management Strategies:

• Increase dose or switch to IV route

• Use continuous infusion rather than bolus

• Combine with thiazide diuretics (sequential nephron blockade)

• Sodium and fluid restriction

• Ultrafiltration in refractory cases

---

13. Monitoring Parameters

• Weight: Daily weight to monitor fluid status

• Urine output: Goal-based targeting (e.g., 500 mL/day negative balance)

• Blood pressure: Especially postural readings

• Serum electrolytes: Na⁺, K⁺, Mg²⁺, Ca²⁺

• Renal function: BUN, serum creatinine

• Hearing function: In high-dose IV use

---

14. Clinical Guidelines and Recommendations

A. Heart Failure:

• ESC and AHA/ACC guidelines recommend loop diuretics to manage signs of congestion

• Initial IV bolus dosing or infusion preferred in acute decompensation

• Dose titration based on urine output (≥150 mL/h considered adequate response)

B. Hypertension:

• Not first-line

• Considered in resistant hypertension or in CKD/volume overload patients

C. Nephrotic Syndrome:

• Often combined with albumin infusion for diuresis in hypoalbuminemia

• Monitor carefully due to risk of hypovolemia

---

15. Research and Future Perspectives

• Loop diuretic combinations with SGLT2 inhibitors in HF and CKD

• Genetic studies on loop transporter polymorphisms and diuretic response

• Biomarkers (e.g., natriuretic peptides) to guide therapy

• Remote monitoring tools for home-based diuretic titration in heart failure

• Inhaled loop diuretics under research for pulmonary conditions

---

16. Summary of Key Points

• Loop diuretics are the most potent diuretic class used in a wide range of edematous conditions

• They act at the thick ascending loop of Henle, inhibiting Na⁺/K⁺/Cl⁻ reabsorption

• Agents include furosemide, bumetanide, torsemide, and ethacrynic acid

• Monitor closely for electrolyte disturbances, dehydration, ototoxicity, and renal dysfunction

• Resistance is common; strategies include combination therapy and IV administration

• Essential in acute heart failure, nephrotic syndrome, and severe hypercalcemia management